We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
20 hedge funds and large institutions have $8.14M invested in CASI Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
320% more capital invested
Capital invested by funds: $1.94M → $8.14M (+$6.2M)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
7.24% more ownership
Funds ownership: 2.63% → 9.87% (+7.2%)
13% less funds holding
Funds holding: 23 → 20 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
75% less call options, than puts
Call options by funds: $2K | Put options by funds: $8K
Holders
20
Holders Change
-3
Holders Change %
-13.04%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
2
Closed
5
Calls
$2K
Puts
$8K
Net Calls
-$6K
Net Calls Change
-$7K
Top Buyers
| 1 |
VA
VR Adviser
New York
|
+$5.66M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$366K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$197K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$147K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.7K |
